Cerliponase alfa

Cerliponase alfa Brand Name– Brineura

What is Cerliponase alfa

Cerliponase alfa is an enzyme replacement therapy for the management of patients with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), a form of Batten disease. CLN2 is a rare, genetic, fatal neurodegenerative disease caused by a deficiency of the lysosomal enzyme tripeptidyl peptidase-1 (TPP1).

Cerliponase alfa is a recombinant form of TPP1 that is administered into the cerebrospinal fluid (CSF) by intraventricular infusion using a specific surgically implanted intraventricular access device.

Patients must be monitored closely during administration for cardiac adverse events and/or hypersensitivity reactions.

Indications & Dosage

  • late-infantile neuronal ceroid lipofuscinosis type 2

For the treatment of patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a form of Batten disease

NOTE: The FDA has designated cerliponase alfa as an orphan drug for this indication.

Side Effects

  1. anaphylactoid reactions
  2. antibody formation
  3. bradycardia
  4. fever
  5. headache
  6. hematoma
  7. hypotension
  8. hypoxia
  9. infection
  10. irritability
  11. seizures
  12. sinus tachycardia
  13. ST-T wave changes
  14. vomiting

Monitoring Parameters

  • cerebrospinal fluid (CSF) assessment
  • ECG

Contraindications

  • bradycardia
  • breast-feeding
  • cardiac disease
  • infection
  • pregnancy
  • requires an experienced clinician
  • serious hypersensitivity reactions or anaphylaxis
  • ventriculoperitoneal (VP) shunt

Interactions

There are no drug interactions associated with Cerliponase alfa products.

15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top